Evidence map›Paper›PMID 37012549›Full record

Trial reportNature medicine2023

Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.

Eugene Shenderov, Angelo M De Marzo, Tamara L Lotan, Hao Wang, Sin Chan, Su Jin Lim, Hongkai Ji, Mohamad E Allaf, Carolyn Chapman, Paul A Moore and 14 more

Open access · greenAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 3 pooled it
24.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 3 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly Expressed, Combinatorial Therapeutic Target.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  8. B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities across Patient Groups with Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  9. Preclinical Activity of the B7-H3-Targeting Antibody-Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  10. Article
  11. Development and Preclinical Evaluation ofJournal of medicinal chemistry · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 2 countries.

Eugene ShenderovDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. Eugene.Shenderov@jhmi.edu.ORCID http://orcid.org/0000-0001-9886-8542
Angelo M De MarzoDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-4847-5307
Tamara L LotanDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-0494-9067
Hao WangDepartment of Oncology Biostatistics and Bioinformatics, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-6489-6940
Sin ChanDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Su Jin LimDepartment of Oncology Biostatistics and Bioinformatics, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Hongkai JiDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-6480-0141
Mohamad E AllafDepartment of Urology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Carolyn ChapmanDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Paul A MooreMacroGenics, Inc., Rockville, MD, USA.
Francine ChenMacroGenics, Inc., Rockville, MD, USA.
Kristina SorgNanoString Technologies Inc., Seattle, WA, USA.
Andrew M WhiteNanoString Technologies Inc., Seattle, WA, USA.
Sarah E ChurchNanoString Technologies Inc., Seattle, WA, USA.ORCID http://orcid.org/0000-0002-7194-4282
Briana HudsonNanoString Technologies Inc., Seattle, WA, USA.
Paul A FieldsAdaptive Biotechnologies, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-9608-6464
Shaohui HuCDI Labs, Baltimore, MD, USA.
Samuel R DenmeadeDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Kenneth J PientaDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-4138-2186
Christian P PavlovichDepartment of Urology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Ashley E RossDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Charles G DrakeImmuno-Oncology, Janssen, Horsham, PA, USA.
Drew M PardollDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Emmanuel S AntonarakisDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-0031-9655
Johns Hopkins University · USNanostring Technologies (United States) · USBloomberg (United States) · USMacroGenics (United States) · USAdaptive Biotechnologies (United States) · USCDI Laboratories (United States) · PRJanssen (United States) · USNorthwestern University · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI NELSON, WILLIAM GEORGE · 1992 to 2020
$43.9M
NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA058236
6 · The paper itself

Abstract

B7 homolog 3 (B7-H3; CD276), a tumor-associated antigen and possible immune checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early recurrence and metastasis. Enoblituzumab is a humanized, Fc-engineered, B7-H3-targeting antibody that mediates antibody-dependent cellular cytotoxicity. In this phase 2, biomarker-rich neoadjuvant trial, 32 biological males with operable intermediate to high-risk localized PCa were enrolled to evaluate the safety, anti-tumor activity and immunogenicity of enoblituzumab when given before prostatectomy. The coprimary outcomes were safety and undetectable prostate-specific antigen (PSA) level (PSA

Indexed as

Antineoplastic AgentsProstatic NeoplasmsAntibodies, MonoclonalB7 AntigensHumansMaleNeoadjuvant TherapyProstate-Specific AntigenAntibodies, MonoclonalAntineoplastic AgentsB7 AntigensCD276 protein, humanProstate-Specific Antigen

Identifiers

PMID37012549
PMCPMC10921422
OpenAlexW4362523806

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.